<DOC>
	<DOCNO>NCT01779453</DOCNO>
	<brief_summary>This study ass safety , atorvastatin pharmacokinetics , LDL-C lower efficacy ETC-1002 versus placebo hypercholesterolemic subject background therapy atorvastatin 10 mg .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetic Drug Interaction Efficacy ETC-1002 Atorvastatin Subjects With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>For subject current daily statin therapy LDLC 100220 mg/dL triglyceride &lt; 350 mg/dL ( prior switching sponsor provide atorvastatin 10 mg/day stop lipidregulating drug supplement ) S1 Visit , For subject current daily statin therapy LDLC ≥ 110 mg/dL ≤ 220 mg/dL Acute significant cardiovascular disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Combination therapy</keyword>
</DOC>